Immunogenicity and prediction of epitopic region of antigen Ag I/II and glucosyltransferase from Streptococcus mutans

Abstract

The levels of Streptococcus (S.) mutans infections in saliva were evaluated and a comparison for specific antibody levels among children with different levels of S. mutans infection was made. The promising epitopic regions of antigen AgI/II (PAc) and glucosyltransferase (GTF) for potential vaccine targets related to S. mutans adherence were screened. A total of 94 children aged 3–4 years were randomly selected, including 53 caries-negative and 41 caries-positive children. The values of S. mutans and those of salivary total secretory immunoglobulin A (sIgA), anti-PAc and anti-Glucan binding domain (anti-GLU) were compared to determine the correlation among them. It was found the level of s-IgA against specific antigens did not increase with increasing severity of S. mutans infection, and the complete amino acid sequence of PAc and GTFB was analyzed using the DNAStar Protean system for developing specific anti-caries vaccines related to S. mutans adherence. A significantly positive correlation between the amount of S. mutans and children decayed, missing, and filled teeth index was observed. No significant difference was detected in specific sIgA against PAc or GLU between any two groups. No significant correlation was found between such specific sIgA and caries index. A total of 16 peptides from PAc as well as 13 peptides from GTFB were chosen for further investigation. S. mutans colonization contributed to early children caries as an important etiological factor. The level of sIgA against specific antigens did not increase with increasing severity of S. mutans infection in children. The epitopes of PAc and GTF have been screened to develop the peptide-based or protein-based anti-caries vaccines.

References

[1] HamadaS, SladeHD. Biology, immunology, and cariogenicity of Streptococcus mutans. Microbiol Rev, 1980, 44(2): 331-384

[2] LiuGX, XuQA, JinJ, et al.. Mucosal and systemic immunization with targeted fusion anti-caries DNA plasmid in young rats. Vaccine, 2009, 27(22): 2940-2947

[3] Oral health surveys. Basic methods, 4th ed. Geneva: World Health Organizaiton, 1997.

[4] LiY, GeY, SaxenaD, et al.. Genetic profiling of the oral microbiota associated with severe early-childhood caries. J Clin Microbiol, 2007, 45(1): 81-87

[5] XuQA, YuF, FanMW, et al.. Protective efficacy of a targeted anti-caries DNA plasmid against cariogenic bacteria infections. Vaccine, 2007, 25(7): 1191-1195

[6] van DolleweerdCJ, KellyCG, ChargelegueD, et al.. Peptide mapping of a novel discontinuous epitope of the major surface adhesin from Streptococcus mutans. J Bio Chem, 2004, 279(21): 22198-22203

[7] KorthC, StierliB, StreitP, et al.. Prion (PrPSc)-specific epitope defined by a monoclonal antibody. Nature, 1997, 390(6655): 74-77

[8] MoraM, TelfordJL. Genome-based approaches to vaccine development. J Mol Med, 2010, 88(2): 143-147

[9] LarsonMR, RajashankarKR, PatelMH, et al.. Elongated fibrillar structure of a streptococcal adhesin assembled by the high-affinity association of alpha-and PPII-helices. Proc Natl Acad Sci USA, 2010, 107(13): 5983-5988

[10] RobinetteRA, OliMW, McArthurWP, et al.. Beneficial immunomodulation by Streptococcus mutans anti-P1 monoclonal antibodies is Fc independent and correlates with increased exposure of a relevant target epitope. J Immunol, 2009, 183(7): 4628-4638

[11] ZhangS, GreenNM, SitkiewiczI, et al.. Identification and characterization of an antigen I/II family protein produced by group A Streptococcus. Infect Immun, 2006, 74(7): 4200-4213

[12] HoshinoT, KondoY, SaitoK, et al.. Novel epitopic region of glucosyltransferase B from Streptococcus mutans. Clin Vaccine Immunol, 2011, 18(9): 1552-1561

[13] PeriC, GagniP, CombiF, et al.. Rational epitope design for protein targeting. ACS Chem Biol, 2013, 8(2): 397-404

[14] van DolleweerdCJ, KellyCG, ChargelegueD, et al.. Peptide mapping of a novel discontinuous epitope of the major surface adhesin from Streptococcus mutans. J Biol-Chem, 2004, 279(21): 22198-22203

[15] LeeLA, WangQ. Adaptations of nanoscale viruses and other protein cages for medical applications. Nanomedicine, 2006, 2(3): 137-149

[16] MamoT, PolandGA. Nanovaccinology: the next generation of vaccines meets 21st century materials science and engineering. Vaccine, 2012, 30(47): 6609-6611

[17] SpendloveL, LiL, PotterV, et al.. A therapeutic human anti-idiotypic antibody mimics CD55 in three distinct regions. Eur J Immunol, 2000, 30(10): 2944-2953

[18] ThomasC, RawatA, Hope-WeeksL, et al.. Aerosolized PLA and PLGA nanoparticles enhance humoral, mucosal and cytokine responses to hepatitis B vaccine. Mol Pharmaceutics, 2011, 8(2): 405-415

[19] ZhaoL, SethA, WibowoN, et al.. Nanoparticle vaccines. Vaccine, 2014, 32(3): 327-337

[20] KanekiyoM, WeiCJ, YassineHM, et al.. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature, 2013, 499(7456): 102-106

RIGHTS & PERMISSIONS

Huazhong University of Science and Technology and Springer-Verlag Berlin Heidelberg